Home > Newsletters > FDAnews Drug Daily Bulletin > Roche Gets Expanded Indication for Actemra in RA Amid Blah Physician Buzz
FDAnews Drug Daily Bulletin
Oct. 17, 2012 | Vol. 9 No. 204
Roche Gets Expanded Indication for Actemra in RA Amid Blah Physician Buzz
The FDA has approved a new indication for Roche’s Actemra to treat adults with moderately to severely active rheumatoid arthritis (RA) who have responded poorly to one or more disease-modifying anti-rheumatic drugs. The regulatory nod makes Actemra (tocilizumab) the first humanized IL-6 receptor-inhibiting monoclonal antibody approved for such an indication, Roche’s Genentech unit said.
Drug Industry Daily
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.